MDC and NMD4C Hiring Full-Time Clinical Trials and Community Practice Manager

Muscular Dystrophy Canada is hiring a full-time Clinical Trials and Community of Practice Manager to support our Clinical Trial Network and Community of Practice task groups and help bring clinical trials to Canada!

Join our team of dedicated colleagues and volunteers in breaking down barriers for the neuromuscular community. Work closely with clinicians, NMD4C investigators and members, industry, government, clinical trial Principal Investigators, the Canadian Neuromuscular Disease Registry (CNDR) and the Care and Trial Site Registry (CTSR) in Canada to ensure a coordinated approach to clinical trials.

Read the full job description here!

MDC and NMD4C now recruiting: clinical trials and community of practice manager

Read next...

2024 NMD4C early-career awards now accepting applications

Annual NMD4C Early-Career Awards Program Accepting Applications

We are excited to launch the second year of the NMD4C Early-Career Awards for 2024!

NMD4C pre-clinical science team seeking trainee input. Let us know if you'd like to be involved in an advisory committee.

NMD4C Pre-clinical Science Pillar Seeking Trainee Input

The NMD4C cell and animal-based research team is actively seeking the input of neuromuscular trainees to help inform our activities. If you are willing to participate in a committee that will meet periodically to share input on NMD4C cell and animal-based research activities, we want to hear from you! 

Dr Natasha Chang and Dr Rashmi Kothary receive MDC Dr David Green Awards in 2023.

NMD4C Investigators Dr Rashmi Kothary and Dr Natasha Chang Receive MDC Awards

We are excited to share that NMD4C investigators Dr Rashmi Kothary, and Dr Natasha Chang received the Dr George Karpati Award for Researcher of the Year and Rising Clinician/Researcher Award respectively from Muscular Dystrophy Canada

News update reading: Vamorolone receives approval by the FDA in the US and positive opinion from CHMP in the EU for use in the treatment of Duchenne muscular dystrophy.

Vamorolone receives approval by the FDA in the US and positive opinion from CHMP in the EU for use in the treatment of Duchenne muscular dystrophy.

The FDA approved vamorolone on October 26, 2023 for the treatment of DMD in the US, while the CHMP has issued a positive opinion for vamorolone for the treatment of DMD in the EU.

NMD4C members gather for a group photo at the annual meeting.

Annual NMD4C Meeting Recap

Thank you to everyone who attended the Annual NMD4C Meeting on September 7th in Ottawa! We were thrilled to welcome 84 network investigators, general members, patient partners and trainees to outline the network activities for the next five years and kick off our new grant period.    The meeting program consisted of presentations from task…

CNDR logo4x3

National Consensus Meeting to Decide Outcome Measures for Adults with SMA

On September 9th and 10th in Ottawa, Ontario, 14 adult SMA experts including, clinicians, allied health care providers, patient organization representatives, and the CNDR representatives gathered to reach an updated national consensus on outcome measures for adults with SMA.